Geovax Labs Inc (GOVX)

$0.514

Market is closed - opens 7 PM, 02 Oct 2023

Insights on Geovax Labs Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 82.6% return, outperforming this stock by 135.4%

Performance

  • $0.51
    $0.52
    $0.51
    downward going graph

    0.0%

    Downside

    Day's Volatility :2.6%

    Upside

    2.6%

    downward going graph
  • $0.51
    $1.39
    $0.51
    downward going graph

    0.88%

    Downside

    52 Weeks Volatility :63.63%

    Upside

    63.31%

    downward going graph

Returns

PeriodGeovax Labs IncSector (Health Care)Index (Russel 2000)
3 Months
-6.55%
-3.0%
0.0%
6 Months
-21.53%
0.5%
0.0%
1 Year
-52.84%
6.3%
6.3%
3 Years
-58.88%
22.1%
17.3%

Highlights

Market Capitalization
13.6M
Book Value
$0.65
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.74
PEG Ratio
0.0
Wall Street Target Price
6.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-45.44%
Return On Equity TTM
-85.79%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
81.5K
EBITDA
-19.7M
Diluted Eps TTM
-0.74
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.83
EPS Estimate Next Year
-0.81
EPS Estimate Current Quarter
-0.16
EPS Estimate Next Quarter
-0.15

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Geovax Labs Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1067.32%

Current $0.51
Target $6.00

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Geovax Labs Inc
Geovax Labs Inc
-15.34%
-21.53%
-52.84%
-58.88%
-58.88%
Moderna, Inc.
Moderna, Inc.
-11.43%
-29.94%
-12.65%
45.99%
455.32%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.44%
1.41%
19.47%
47.01%
108.75%
Novo Nordisk A/s
Novo Nordisk A/s
-3.29%
15.05%
82.56%
161.96%
290.64%
Seagen, Inc.
Seagen, Inc.
2.56%
4.47%
55.05%
8.41%
161.4%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.86%
11.4%
20.1%
27.79%
81.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Geovax Labs Inc
Geovax Labs Inc
NA
NA
0.0
-0.83
-0.86
-0.45
0.0
0.65
Moderna, Inc.
Moderna, Inc.
34.94
34.94
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.08
22.08
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.05
43.05
2.03
1.64
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.67
26.67
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Geovax Labs Inc
Geovax Labs Inc
Buy
$13.6M
-58.88%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.2B
455.32%
34.94
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.6B
108.75%
22.08
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$412.6B
290.64%
43.05
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$39.8B
161.4%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$89.7B
81.52%
26.67
35.4%

Institutional Holdings

  • Vanguard Group Inc

    2.76%

  • BlackRock Inc

    1.56%

  • Geode Capital Management, LLC

    0.65%

  • State Street Corporation

    0.37%

  • Morgan Stanley - Brokerage Accounts

    0.19%

  • TWO SIGMA SECURITIES, LLC

    0.14%

Company Information

geovax labs, inc., (otcqb: govx) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our modified vaccinia ankara - virus-like particle (mva-vlp) vaccine platform. our development programs are focused on preventive vaccines against hiv, zika virus, hemorrhagic fever viruses (ebola, sudan, marburg, and lassa), and malaria, as well as therapeutic vaccines for chronic hepatitis b infections and cancers. our mva-vlp platform supports in vivo production of non-infectious vlps from the cells of the very person receiving the vaccine, mimicking a natural infection, and stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. for more information, visit www.geovax.com.

Organization
Geovax Labs Inc
Employees
14
CEO
Mr. David Alan Dodd
Industry
Biotechnology

Discover More

FAQs